Literature DB >> 12112659

Comparison of DNA- and RNA-based methods for detection of truncating BRCA1 mutations.

Irene L Andrulis1, Hoda Anton-Culver, Jeanne Beck, Betsy Bove, Jeff Boyd, Saundra Buys, Andrew K Godwin, John L Hopper, Frederick Li, Susan L Neuhausen, Hilmi Ozcelik, David Peel, Regina M Santella, Melissa C Southey, Nathalie J van Orsouw, Deon J Venter, Jan Vijg, Alice S Whittemore.   

Abstract

A number of methods are used for mutational analysis of BRCA1, a large multi-exon gene. A comparison was made of five methods to detect mutations generating premature stop codons that are predicted to result in synthesis of a truncated protein in BRCA1. These included four DNA-based methods: two-dimensional gene scanning (TDGS), denaturing high performance liquid chromatography (DHPLC), enzymatic mutation detection (EMD), and single strand conformation polymorphism analysis (SSCP) and an RNA/DNA-based protein truncation test (PTT) with and without complementary 5' sequencing. DNA and RNA samples isolated from 21 coded lymphoblastoid cell line samples were tested. These specimens had previously been analyzed by direct automated DNA sequencing, considered to be the optimum method for mutation detection. The set of 21 cell lines included 14 samples with 13 unique frameshift or nonsense mutations, three samples with two unique splice site mutations, and four samples without deleterious mutations. The present study focused on the detection of protein-truncating mutations, those that have been reported most often to be disease-causing alterations that segregate with cancer in families. PTT with complementary 5' sequencing correctly identified all 15 deleterious mutations. Not surprisingly, the DNA-based techniques did not detect a deletion of exon 22. EMD and DHPLC identified all of the mutations with the exception of the exon 22 deletion. Two mutations were initially missed by TDGS, but could be detected after slight changes in the test design, and five truncating mutations were missed by SSCP. It will continue to be important to use complementary methods for mutational analysis. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12112659     DOI: 10.1002/humu.10097

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  29 in total

1.  Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States.

Authors:  Yuan Chun Ding; Linda Steele; Chih-Jen Kuan; Scott Greilac; Susan L Neuhausen
Journal:  Breast Cancer Res Treat       Date:  2010-10-07       Impact factor: 4.872

2.  Identification of mutations from phenotype-driven ENU mutagenesis in mouse chromosome 7.

Authors:  Cymbeline T Culiat; Mitchell L Klebig; Zhaowei Liu; Heidi Monroe; Beverly Stanford; Jayashree Desai; Samvit Tandan; Lori Hughes; Marilyn K Kerley; Donald A Carpenter; Dabney K Johnson; Eugene M Rinchik; Qingbo Li
Journal:  Mamm Genome       Date:  2005-08       Impact factor: 2.957

3.  Smoking and risk of breast cancer in carriers of mutations in BRCA1 or BRCA2 aged less than 50 years.

Authors: 
Journal:  Breast Cancer Res Treat       Date:  2007-10-31       Impact factor: 4.872

4.  Development and characterization of reference materials for MTHFR, SERPINA1, RET, BRCA1, and BRCA2 genetic testing.

Authors:  Shannon D Barker; Sherri Bale; Jessica Booker; Arlene Buller; Soma Das; Kenneth Friedman; Andrew K Godwin; Wayne W Grody; Edward Highsmith; Jeffery A Kant; Elaine Lyon; Rong Mao; Kristin G Monaghan; Deborah A Payne; Victoria M Pratt; Iris Schrijver; Antony E Shrimpton; Elaine Spector; Milhan Telatar; Lorraine Toji; Karen Weck; Barbara Zehnbauer; Lisa V Kalman
Journal:  J Mol Diagn       Date:  2009-09-18       Impact factor: 5.568

5.  Genome-wide DNA methylation assessment of 'BRCA1-like' early-onset breast cancer: Data from the Australian Breast Cancer Family Registry.

Authors:  Cameron M Scott; Ee Ming Wong; JiHoon Eric Joo; Pierre-Antoine Dugué; Chol-Hee Jung; Neil O'Callaghan; James Dowty; Graham G Giles; John L Hopper; Melissa C Southey
Journal:  Exp Mol Pathol       Date:  2018-11-10       Impact factor: 3.362

6.  Breast cancer risk for noncarriers of family-specific BRCA1 and BRCA2 mutations: findings from the Breast Cancer Family Registry.

Authors:  Allison W Kurian; Gail D Gong; Esther M John; David A Johnston; Anna Felberg; Dee W West; Alexander Miron; Irene L Andrulis; John L Hopper; Julia A Knight; Hilmi Ozcelik; Gillian S Dite; Carmel Apicella; Melissa C Southey; Alice S Whittemore
Journal:  J Clin Oncol       Date:  2011-10-31       Impact factor: 44.544

7.  CK8/18 expression, the basal phenotype, and family history in identifying BRCA1-associated breast cancer in the Ontario site of the breast cancer family registry.

Authors:  Anna Marie Mulligan; Dushanthi Pinnaduwage; Anita L Bane; Shelley B Bull; Frances P O'Malley; Irene L Andrulis
Journal:  Cancer       Date:  2010-11-02       Impact factor: 6.860

8.  BRCA1 and BRCA2 mutation carriers in the Breast Cancer Family Registry: an open resource for collaborative research.

Authors:  Susan L Neuhausen; Hilmi Ozcelik; Melissa C Southey; Esther M John; Andrew K Godwin; Wendy Chung; Jeniffer Iriondo-Perez; Alexander Miron; Regina M Santella; Alice Whittemore; Irene L Andrulis; Saundra S Buys; Mary B Daly; John L Hopper; Daniela Seminara; Ruby T Senie; Mary Beth Terry
Journal:  Breast Cancer Res Treat       Date:  2008-08-14       Impact factor: 4.872

Review 9.  Methods for meta-analysis in genetic association studies: a review of their potential and pitfalls.

Authors:  Fotini K Kavvoura; John P A Ioannidis
Journal:  Hum Genet       Date:  2007-11-17       Impact factor: 4.132

10.  Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors.

Authors:  Anita L Bane; Dushanthi Pinnaduwage; Sarah Colby; Michael Reedijk; Sean E Egan; Shelley B Bull; Frances P O'Malley; Irene L Andrulis
Journal:  Breast Cancer Res Treat       Date:  2008-06-18       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.